priors.science/reviews/pulmonary-arterial-hypertension-treatment

Pulmonary Arterial Hypertension Treatment

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked

30 May 2026latest evidence review

Weeklyre-scored against new papers

11 Established · 7 Likely · 2 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableERA plus PDE5 inhibitor outperforms monotherapy in PAHCombinationEstablished91%—

StableSelexipag reduces morbidity and mortality risk in PAHProstacyclinEstablished91%—

StableSotatercept improves 6-minute walk distance in PAHSotaterceptEstablished90%—

StableSSc-PAH has worse prognosis than idiopathic PAHCTDEstablished89%—

StableSotatercept reduces clinical worsening in high-risk PAHSotaterceptEstablished89%—

StableMacitentan reduces morbidity and mortality in PAHEraEstablished88%—

StableIntravenous epoprostenol improves survival in severe PAHProstacyclinEstablished88%—

StableLow-risk status at follow-up improves PAH survivalRiskEstablished88%—

StableSotatercept exercise capacity add-onSotaterceptEstablished88%—

StableInhaled treprostinil improves 6MWD in PH-ILDProstacyclinEstablished87%—

StableFour-strata COMPERA outperforms three-strata risk scoring in PAHRiskEstablished85%—

StableREVEAL 2.0 accurately predicts one-year survival in PAHRiskLikely83%—

StableModern PAH therapy has substantially improved long-term survivalRiskLikely83%—

StableMacitentan improves haemodynamics in portopulmonary hypertensionEraLikely82%—

StableMacitentan-tadalafil combination improves 6MWD in PAHEraLikely77%—

StablePAH therapies are less effective in SSc-PAHCTDLikely75%—

StableUpfront triple therapy outperforms double therapy in PAHCombinationLikely68%—

StableOral treprostinil improves outcomes in PAH on background therapyProstacyclinLikely66%—

StableRituximab improves haemodynamics and outcomes in SSc-PAHCTDUncertain50%—

StableTriple therapy confers no benefit over dual in low-risk PAHCombinationUncertain44%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic